Article
Molecular Biomarker and Programmed Death-Ligand 1 Expression Testing in Patients With Advanced Stage Non-small Cell Lung Cancer Across North Carolina Community Hospitals.
Chest - 1 Sept 2021
Rivera M Patricia, Charlot Marjory, Durham Danielle D, Throneburg Allison, Lane Lindsay M, Perera Pasangi, Samulski Teresa D, Henderson Louise M
Abstract excerpt
BACKGROUND: Precision medicine in advanced non-small cell lung cancer (NSCLC) requires molecular biomarker testing in patients with nonsquamous and select patients with squamous histologies, and programmed death-ligand 1 (PD-L1) testing in both. RESEARCH QUESTION: What are rates of molecular and PD-L1 biomarker testing in patients with advanced NSCLC in community practices, and do rates vary by sociodemographic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.